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Background: Metabotropic glutamate receptors (mGluRs) have been identified as significant analgesic targets.
Systemic treatments with inhibitors of the enzymes that inactivate the peptide transmitter N-acetylaspartylglutamate
(NAAG), an mGluR3 agonist, have an analgesia-like effect in rat models of inflammatory and neuropathic pain. The
goal of this study was to begin defining locations within the central pain pathway at which NAAG activation of its
receptor mediates this effect.
Results: NAAG immunoreactivity was found in neurons in two brain regions that mediate nociceptive processing,
the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM). Microinjection of the NAAG peptidase
inhibitor ZJ43 into the PAG contralateral, but not ipsilateral, to the formalin injected footpad reduced the rapid and
slow phases of the nociceptive response in a dose-dependent manner. ZJ43 injected into the RVM also reduced the
rapid and slow phase of the response. The group II mGluR antagonist LY341495 blocked these effects of ZJ43 on the
PAG and RVM. NAAG peptidase inhibition in the PAG and RVM did not affect the thermal withdrawal response in the
hot plate test. Footpad inflammation also induced a significant increase in glutamate release in the PAG. Systemic
injection of ZJ43 increased NAAG levels in the PAG and RVM and blocked the inflammation-induced increase in
glutamate release in the PAG.
Conclusion: These data demonstrate a behavioral and neurochemical role for NAAG in the PAG and RVM in
regulating the spinal motor response to inflammation and that NAAG peptidase inhibition has potential as an
approach to treating inflammatory pain via either the ascending (PAG) and/or the descending pain pathways
(PAG and RVM) that warrants further study.
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Each of the current analgesic therapies has limited effi-
cacy in treating inflammatory and neuropathic pain and
some have significant side effects. As a result, there is a
need to develop drugs with different targets in the noci-
ceptive processing pathway. The heterotropic group II
metabotropic glutamate receptor (mGluR2 and mGluR3)
agonists have shown analgesic efficacy in animal models
of inflammatory and neuropathic pain [1]. Consistent* Correspondence: nealej@georgetown.edu
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reproduction in any medium, provided the orwith this, activation of the type 3 metabotropic “glutamate”
receptor (mGluR3) by the peptide neurotransmitter
N-acetylaspartylglutamate (NAAG) reduces the flinching
response to peripheral inflammation, reduces hyperalgesia
induced by peripheral neuropathy and moderates the pain
response in a model of bone cancer [2-9].
NAAG is one of the most prevalent transmitters in the
mammalian nervous system [10]. It activates presynaptic
mGluR3 receptors resulting in reductions in cAMP and
cGMP levels [11-15], reduction in depolarization-induced
calcium influx and inhibition of transmitter release [16-20].
The enzymes that inactivate synaptically released NAAG
have been cloned [21-25] and potent inhibitors of thesel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tration of these inhibitors, including ZJ43, reduces pain
responses in animal models [2,4-9,28,29].
This research aimed to provide further insight into the
mechanism of NAAG’s action in the pain processing path-
way. We directly tested the hypothesis that the analgesic-
like effects of NAAG peptidase inhibition in the formalin
model of inflammation are mediated centrally in two well-
recognized regions of the ascending and descending pain
pathways, the periaqueductal gray (PAG) and the rostral
ventromedial medulla (RVM). In parallel, the efficacy of
systemically administered ZJ43 in elevating extracellular
NAAG levels was assessed in these brain regions as was
the influence of NAAG on the levels of inflammation-
induced glutamate release.
Results
Using highly specific, multi-stage affinity purified anti-
bodies (see Methods), NAAG immunoreactivity was
observed in neurons and axons in the rat PAG and RVM
(Figure 1a,b). Consistent with the potential of this trans-
mitter to regulate neurotransmission via activation of pre-
synaptic receptors in these brain regions, putative
NAAGergic synapses were observed on the cell bodies
and dendrites of PAG neurons, as well as in the neuropil
(Figure 1c). While these data alone are insufficient to con-
firm the synaptic localization of this immunoreactivity,
studies with this antibody at the ultrastructural level previ-
ously localized NAAG immunoreactivity to synaptic vesi-
cles [30] and optic nerve transection studies demonstrated
that NAAG immunoreactivity is associated with NAAG-
containing synaptic terminals in various regions of the
CNS [31,32]. Additionally, depolarization-induced cal-
cium-dependent NAAG release has been demonstrated
repeatedly [10,33]. These data on the presence of NAAG
in the PAG and RVM provided a rationale for microinjec-
tion of the NAAG peptidase inhibitor ZJ43 into these
regions of the pain transmission pathway.
Subcutaneous injection of formalin in the rat footpad
produced a reliable biphasic display of flinching of the
injected paw (Figure 2) consistent with our previous studies
[6-8]. Microinjection of ZJ43 (150 μg) into the PAG contra-
lateral to the inflamed footpad significantly decreased the
number of flinches in both the early and late phase. These
effects of ZJ43 were dose-dependent (Figure 3) and blocked
by i.p. injection with the mGluR2/3 receptor antagonist
LY341495 (Figure 4, p< 0.05). We previously found that
systemic injection of this antagonist alone had no signifi-
cant effect on the response in the formalin or sciatic nerve
ligation tests although a ceiling affect in the former and
floor effect in the latter could have precluded detecting a
change in response [6-8,29]. To confirm the restricted dis-
tribution of the peptidase inhibitor from the injection site,
particularly its close proximity to the aqueduct, ZJ43 wasinjected into the PAG ipsilateral to injected footpad. The
ipsilateral injection response was significantly different
from the response following contralateral PAG injection
(Figure 5, Phase 1: ipsilateral, 36.4±6.5; contralateral,
12.7± 2.1, p< 0.005; Phase 2: ipsilateral, 136±21.5; contra-
lateral, 79.4 ±7.8, p< 0.05) and not significantly different
from the response following saline injection into the
contralateral PAG (Phase 1: 34.7± 5.5; Phase 2: 156±15.6).
NAAG-like immunoreactivity was found in the RVM, in-
cluding the nucleus raphe magnus (Figure 1b). Microinjec-
tion of ZJ43 (150 μg) into the RVM also significantly
reduced flinching in the rapid (p< 0.001) and slow
(p< 0.01) phases of the inflammatory pain response
(Figure 6a, b). The mGluR 2/3 antagonist LY341495 (i.p.)
again reduced the effect of the peptidase inhibitor on the
first phase of the flinching response (p< 0.05) and blocked
the effect in the slow phase (p< 0.01) (Figures 6a, b). ZJ43
was effective in a dose-dependent manner (p <0.05) in
both phases of the flinching response (Figure 7).
Consistent with our previous reports that systemically
administered ZJ43 and 2-PMPA failed to affect the thermal
response latency [3,4], microinjection of ZJ43 (150 μg) into
the PAG or RVM had no effect on the response in the hot
plate test (Figure 8).
Our model of the efficacy of NAAG peptidase inhibition
[3,33] predicts that ZJ43 will increase the extracellular
levels of the peptide that in turn will activate presynaptic
mGluR3 receptors to reduce release of glutamate or other
transmitters. To test this, ZJ43 (150 mg/kg) was injected
(i.p.) 15 minutes prior to footpad inflammation. This i.p.
dose previously has been shown to reduce both the rapid
and slow phase of the flinching response [6]. NAAG and
glutamate levels were assessed by microdialysis in the
PAG and RVM.
Formalin injection had no effect on NAAG levels in
PAG and RVM (Figure 9a, b). ZJ43 increased NAAG levels
by ~20-fold. There was a significant difference in NAAG
levels between groups in the 0–140 min PAG dialysate
samples (p< 0.01), and an overall time× group interaction
was observed for NAAG in PAG (F6, 36 = 7.711, p< 0.001).
There was a significant difference in NAAG levels between
groups in the 0-140 min RVM dialysate sample (p< 0.001)
and an overall time× group interaction was observed for
NAAG in RVM (F6, 60= 24.368, p< 0.001).
Formalin injection into the footpad resulted in a 40% in-
crease in glutamate release over baseline in the contralat-
eral PAG between 5 and 25 minutes after the inflammatory
insult (Figure 10a). Systemic injection of ZJ43 (150 mg/kg,
i.p.) blocked this increase in glutamate release as our
model predicted. There was a significant difference in glu-
tamate levels between groups in the 20–40 min dialysate
sample (p< 0.05), and an overall time×group interaction
also was observed for glutamate (F2, 16 = 5.57, p< 0.05). In
the contralateral RVM, there was a small and not
Figure 1 a: NAAG immunoreactivity in neurons and processes of the lateral periaqueductal gray (PAG). Regions denoted with letters in
panel A show the areas of enlargement found in panels B – D. NAAG staining was relatively light in the region immediately surrounding the
cerebral aqueduct (AQ), which contained small NAAG stained neurons and fine immunoreactive fibers (arrows in B). More neurons and processes
were strongly immunoreactive for NAAG at the periphery of the PAG (C and D). The finely punctate staining represents high concentrations of
NAAG as would be found in synaptic endings. Bar = 15 μm B – D. b: NAAG immunoreactivity in the raphe magnus (RM) of the brainstem (A).
NAAG staining in the RM was similar to adjacent reticular areas with numerous moderately to strongly immunoreactive neurons. Many neuronal
processes were immunoreactive for NAAG in the RM (B). Bar = 30 μm in B. c: NAAG-immunoreactivity in apparent synaptic contacts on neurons in
the lateral PAG. Areas within boxes in A and C are enlarged in B and D. Panel A is from a region immediately adjacent to the cerebral aqueduct
and Panel C is slightly further from the aqueduct. Apparent NAAG-containing synaptic contacts were observed on the surface of perikarya, major
dendrites, and in the neuropil. Images acquired with extended depth of field. Bar = 5 μm B and D.
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Figure 2 Effect of microinjection of ZJ43 into the PAG. Saline or
ZJ43 or ZJ43 with LY341495 were microinjected into the right PAG
10 min prior to formalin injection into the dorsal surface of the
contralateral footpad (0 time). Formalin injection induced two
phases of hindpaw flinching in the saline injected control rats
(n = 6). Microinjection of 150 μg of ZJ43 (n = 7) reduced both phases
of the formalin-induced pain response. Pre-treatment with 1 mg/kg
of the group II mGluR antagonist LY341495 (i.p.) (n = 6) reversed the
effect of ZJ43 on the rapid and slow responses. Ordinate: number of
flinches per min; abscissa: time after drug administration (min). Data
in this and subsequent figures are presented as the mean +/− S.E.M.
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sponse to footpad inflammation and this was unaffected by
systemic ZJ43 treatment (Figure 10b). The use of a smaller
dialysis probe (1 mm vs 2 mm) similarly showed no effect
of inflammation on glutamate levels in the RVM.
Discussion
Current analgesic therapies typically inhibit cyclooxygen-
ase enzymes or activate opiate receptors. Each of these
front line analgesics for treatment of inflammatory and
neuropathic pain has some negative clinical consequences
or lacks efficacy in a significant proportion of patients.
Adjuvant analgesics, including antidepressants (SSRIs),
anticonvulsants (gabapentin, pregabalin) and anestheticsFigure 3 ZJ43 dose response in the PAG. Dose–response curves for ZJ4
presenting the cumulative instances of formalin-evoked flinches during ph
represents sum of flinches by saline treated rats. ZJ43 or saline was microin
represents the mean of five to seven rats. ZJ43 reduced phase 1 and phase
compared with the phase 1 or phase 2 responses in the saline treated rats(mexiletine, lidocaine) are sometimes effective in relieving
pain. However, they do not represent widely effective
treatments for relief of chronic inflammatory or neuro-
pathic pain or hyperalgesia.
The NAAG receptor, mGluR3, is widely expressed by
neurons and glia in the nervous system including the PAG
and RVM [34]. The observation of NAAG immunoreactiv-
ity (Figures 1a–c) in the ascending and descending pain
pathway supports the potential of NAAG peptidase inhibi-
tors to affect the response to inflammation.
The efficacy of NAAG peptidase inhibition in the PAG is
consistent with the report that intra-PAG injection of the
group II mGluR agonist L-CCG-I also reduces responses
in the formalin model [35]. In previous studies, we found
that peripheral [8], intrathecal [4] and intracerebroventri-
cular [7] administration of NAAG peptidase inhibitors had
similar analgesia-like properties in the formalin test. The
data in this manuscript provide the first insight into the
potential of NAAG and the inhibitors of its inactivation to
influence the ascending (PAG) and descending (RVM and
PAG) pain pathways. Given the expression of mGluR3
receptors and NAAG in the spinal cord and spinal sensory
neurons [10,33], our previous studies and the data pre-
sented here suggest that, like opiate peptides, NAAG has
the potential to moderate the response to inflammatory
pain at several different levels within this pathway. The ef-
ficacy in this model of NAAG peptidase inhibition in the
PAG and RVM support the conclusion that, at a minimum,
the release of NAAG in these regions modulates the spinal
pain response via the descending inhibitory pain pathway.
This hypothesis needs to be further tested in other models
that more clearly assess perception of pain since flinching
in the formalin model can be critiqued as a spinal reflex
that does not reflect cortically based cognition of pain.
Relevant to this question, we previously reported that sys-
temic and intrathecal injections of two NAAG peptidase
inhibitors were highly effective in the sciatic nerve ligation3 injection into the PAG contralateral to the formalin injected site
ase 1 and phase 2 of the formalin test (closed circles). Open circle
jected into PAG 10 min before the formalin injection. Each point
2 flinching behavior 37.5 μg and 150 μg doses. * p< 0.05 as
(open circle).
Figure 4 Sum of flinches following microinjection of saline, ZJ43 or ZJ43 with LY341495 into the PAG. Phase one data are the sum of
flinches for the first 10 min. Phase two data are the sum of flinches from 10–60 min. Data are calculated from Figure 2. * p< 0.05.
Figure 5 ZJ43 microinjected into the PAG ipsilateral to the
inflamed footpad. Comparison of ZJ43 microinjection into the PAG
contralateral and ipsilateral to the inflamed footpad. Ipsilateral data,
n = 6. The contralateral ZJ43 and saline data are from Figure 2.
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NAAG peptidase inhibition to be analgesic in a model of
bone cancer pain [29].
A series of studies demonstrate that NAAG peptidase in-
hibition elevates extracellular NAAG levels with the conse-
quent activation of a group II mGluR (mGluR3), an
activity that inhibits the release of small amine transmitters
including glutamate, GABA, and aspartate, via presynaptic
inhibition [16-20]. While other mechanisms of action are
possible, presynaptic inhibition might well be responsible
for the efficacy of NAAG peptidase inhibitors in animal
models of several nervous system disorders [3].
Figure 10a presents the first demonstration of inflam-
mation-induced increase in glutamate release in the PAG,
a result consistent with increased ascending excitatory sig-
nals from the site of inflammation. Given the efficacy of
ZJ43 microinjection into the PAG in reducing flinching
and increasing extracellular NAAG levels, we examined
the effect of NAAG peptidase inhibition on this inflamma-
tion-induced glutamate release. Systemically applied ZJ43
(50 mg/kg) reaches a concentration of 2 nM in the brain
30 minutes after injection [19] and significantly reduces
NAAG hydrolysis in the rat brain in vivo (Olszewski et al.,
submitted). Its efficacy in blocking this inflammation-
induced glutamate release in the PAG is consistent with
our models of NAAG activation of presynaptic mGluR3
to inhibit transmitter release [3,33]. The difference be-
tween the RVM and PAG with respect to formalin-
induced glutamate release could reflect the role of the
PAG, but not the RVM, in the ascending pain pathway.
While these data demonstrate a role for NAAG in the
control of inflammation-induced glutamate release in the
PAG, they are not sufficient to prove that the NAAG pep-
tidase inhibition-mediated decrease in glutamate release
mediates the observed reduction in the inflammation-
induced motor response.
Microinjection of ZJ43 into the RVM also reduced the
response to footpad inflammation (Figures 6–7) and sys-
temic treatment with this inhibitor also elevated RVM
NAAG levels (Figure 9b). In contrast to the PAG,however, inflammation did not significantly elevate glu-
tamate levels in the RVM. Since microinjection of excita-
tory amino acids into the RVM is analgesic [36], it would
not be expected that formalin treatment would necessarily
produce a substantial increase in glutamate release or that
inhibition of glutamate release in the RVM would mediate
analgesia. One interpretation of these data is that NAAG
activation of mGluR3 receptors inhibited the release of
other transmitters in the RVM with the consequent effect
on the local circuitry [37,38]. For example, inhibition of
GABA release could indirectly result in an increase in re-
lease of other transmitters, whose actions mediate anal-
gesia in the RVM [39,40]. Alternatively, the effect of
formalin injection on glutamate release in the RVM might
have been restricted to a volume of tissue that was smaller
than that sampled by the microdialysis probe resulting in
a failure to detect increases in glutamate levels above the
background in the sampling area. However, a small study
(n= 3) obtained using a smaller (1 mm) dialysis probe tip
in sampling the RVM provided no evidence of an
Figure 6 ZJ43 microinjection into the RVM. Formalin injection into the dorsal surface of the left rat hind-paw induced two phases of hindpaw
flinching in the saline injected control rats (n = 7). a. Microinjection of 150 μg of ZJ43 (n = 7) into the contralateral RVM reduced both of phases of
the pain response observed after the formalin injection. Pre-treatment with 1 mg/kg (i.p.) of the group II mGluR antagonist LY341495 (n = 10)
blocked the effect of ZJ43 in the RVM. b. Sum of flinches following microinjection of saline, ZJ43 or ZJ43 with LY341495 into the RVM. Phase one
data are the sum of flinches for the first 10 min. Phase two data are the sums of flinches from 10–60 min. Data are calculated from Figure 6a.
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Figure 10b.
Heterotropic group II mGluR (mGluR2 and mGluR3)
agonists reduce inflammatory pain responses and also
may represent a novel analgesic strategy [1]. However,
these compounds were tested in mGluR2 and mGluR3
knockout mice in animal models of schizophrenia and
were found to be effective in mGluR3 but not mGluR2
knock outs [41,42]. In the same animal models, NAAG
peptidase inhibition was effective in the mGluR2 but not
the mGluR3 knockout mice [43]. These data support the
conclusion that the heterotropic mGluR2/3 agonists and
mGluR2 positive allosteric modulators have the potential to
be effective mGluR2 based analgesic strategies in contrast
to NAAG peptidase inhibition that represents an mGluR3
specific strategy. Also relevant to the differences between
these two analgesic approaches, pharmacotherapies, such
as antidepressants, sedatives and anxiolytics, that increasethe activity of endogenous transmitters tend to enhance the
normal ongoing physiology and thus can have less potential
for secondary effects than continuous agonist-based recep-
tor activation.
The concept that orally available NAAG peptidase
inhibitors [2,26] might ultimately be used clinically for
the treatment of inflammatory and neuropathic pain
begs the question as to their potential secondary effects
inasmuch as the peptide and mGluR3 are widely distrib-
uted in the nervous system. Studies in mice do not sug-
gest that negative secondary effects result from NAAG
peptidase inhibition [33]. For example, we found no sig-
nificant neurological deficits in mice in which the major
NAAG peptidase, glutamate carboxypeptidase II, had
been knocked out [44]. Similarly, chronic treatment with
a NAAG peptidase inhibitor was without detectable side
effects in a study where the drug increased the lifespan
of mice in a model of amyotrophic lateral sclerosis [45].
Figure 7 Dose–response curves for ZJ43 injection into the midline RVM presenting the cumulative instances of formalin evoked
flinches during phase 1 and phase 2 of the formalin test. Drugs were administered into RVM 10 minutes before the formalin induction of
inflammation. Each point represents the mean of responses of 5–7 rats. ZJ43 reduced phase 1 and phase 2 flinching behavior in a
dose-dependent manner. **p< 0.01; ***p< 0.001 compared with the phase 1 or phase 2 responses in the saline treated rats.
Yamada et al. Molecular Pain 2012, 8:67 Page 7 of 13
http://www.molecularpain.com/content/8/1/67Acute treatment with ZJ43 similarly lacks detectable
effects in open field behavior [20], prepulse inhibition of
acoustic startle [46], or the 1.5 hr delay novel object rec-
ognition test [Olszewski et al., submitted]. Neither sys-
temic NAAG peptidase inhibition [6] nor microinjection
of 150μg of ZJ43 into the PAG and RVM (Figure 8) alter
the reaction time of rats in the hot plate test. This lack
of apparent side effects is consistent with the established
pattern of peptide co-transmitter release under condi-
tions of high neuronal activity with little released during
normal to low levels of activity. Consistent with this
concept, the basal extracellular concentrations of NAAG
and glutamate in the dialysates, uncorrected for recov-
ery, were 53 ± 06 nM and 1,250 ± 130 nM in PAG, 74 ± 5
nM and 820 ± 70 nM in RVM respectively. This differ-
ence in extracellular concentrations also is found in
other brain regions [19,20] despite the fact that NAAG
is present in mM concentrations in the mammalian ner-
vous system [47]. Such a pattern of release is consistent
with our model of NAAG feeding back on presynapticFigure 8 Reaction times of rats placed on a 52.5°C surface following i
Baseline latencies (O time) were established from 3 pretrial tests per anima
administration of saline or 150 μg ZJ43 into the PAG (n = 4, 6) and RVM (nmGluR3 to dampen synaptic release of primary amine
transmitters under conditions of high activity [3].Conclusions
The data presented here provide the first demonstration of:
1) the presence of NAAG within neurons and presumptive
synaptic endings in two discrete regions of the pain proces-
sing pathway of the brain, the PAG and RVM; 2) the eleva-
tion of synaptically released NAAG in these sites by
systemic application of a NAAG peptidase inhibitor; 3) the
analgesic efficacy of NAAG peptidase inhibition directly in
the PAG and RVM; 4) the role of the mGluR3 receptor in
mediating the analgesic efficacy NAAG peptidase inhibition
in the PAG and RVM based on NAAG’s selectivity for this
receptor [11] and the blockade of the effect NAAG peptid-
ase inhibition by co-administration of the mGluR2/3 antag-
onist LY431495. These data support the conclusion that
NAAG peptidase inhibition has potential as an approach to
treating inflammatory pain via either the ascending (PAG)njection of NAAG peptidase inhibitor into the PAG and RVM.
l and reaction times were assessed at different intervals after
= 4, 4).
Figure 9 Microdialysis sampling for NAAG release in the PAG (a) and RVM (b) following inflammation. NAAG levels are expressed as a
percent of the three baseline samples for each animal. ZJ43 (150 mg/kg, i.p.) prior to formalin treatment (Z-F) or saline prior to formalin (S-F).
ZJ43 or saline was injected i.p. at 0 time followed by 50 μl of 5% formalin injected into the contralateral footpad at the 15 min time point. ZJ43
significantly (p< 0.001) increased NAAG levels in the PAG (a) and RVM (b). Samples were collected over 20 minute intervals. *p< 0.05; **p< 0.01;
***p< 0.001.
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warrants further study.
Materials and methods
The Institutional Animal Care and Use Committees at
Georgetown and Kumamoto University approved all ani-
mal procedures. The principles of animal care were con-
sistent with the standards of the US National Institutes of
Health and Department of Agriculture. Male Sprague–
Dawley rats (300–350 g) were housed in groups of two,
maintained on a 12-hour dark–light cycle, and permittedfood and water ad libitum. Animals were handled on ar-
rival and were housed for at least three days before testing.
Behavioral testing was performed between 10.00 h and
16.00 h. Animals were euthanized immediately after be-
havioral or microdialysis studies.
Immunohistochemistry and antibodies
The NAAG specific antisera were prepared and immuno-
histochemistry performed as previously described [48,49].
Briefly, polyclonal NAAG antisera were purified in stages
by both affinity chromatography and negative-affinity
Figure 10 Microdialysis sampling for glutamate release in the PAG and RVM following inflammation as in Figure 9. Glutamate levels are
expressed as a percent of the three baseline samples for each animal. Saline (S-F) or ZJ43 (Z-F, 150 mg/kg, i.p.) was injected at 0 time, formalin at
the 15 minute time point. a. Microdialysis in the PAG. Inflammation significantly increased (p< 0.05) glutamate levels between the 20- and
40-minute time points (5–25 minutes after formalin injection) in the PAG relative to baseline samples. ZJ43 blocked inflammation-induced
glutamate levels relative to saline treatment at over this interval (p< 0.05). b. Microdialysis in the RVM. Formalin-induced changes in extracellular
glutamate levels above baseline were not detected using the standard 2 mm dialysis tip following saline–formalin (S-F) or ZJ43-formalin Z-F)
treatments using the standard 2 mm dialysis tip nor with a 1 mm dialysis tip (S-F-1 mm). *p< 0.05. The same microdialysates samples from the
PAG and RVM were analyzed for both NAAG (Figure 10) and glutamate (Figure 9).
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cluding N-acetylaspartate N-acetylglutamate glutamate, as-
partate and GABA [48]. Rats were transcardially perfused
with 6% carbodiimide and 5% DMSO. Brains were post
fixed with 4% paraformaldehyde, saturated with 30% su-
crose, frozen and sectioned (20 μm). Sections were treated
with 2% normal goat serum prior to incubation with affinity
purified anti-NAAG rabbit serum (1:2,000). Antibodies
were visualized with peroxidase-labeled avidin-biotin com-
plex (Vectastain, Vector Labs, Burlingame, CA) and devel-
oped with H2O2 as substrate for diaminobenzidine aschromogen. Control tissue sections lacking antibody treat-
ment or treated with NAAG blocked antibody exhibited no
specific reaction product above background. These anti-
bodies fail to cross react with glutamate, N-acetylaspartate,
N-acetylglutamate, aspartate or GABA [48,49]. Images were
acquired on an Olympus BX51 microscope and DP71 cam-
era, and were adjusted for contrast and brightness using PC
based software (Adobe Systems). Additional software was
used for enhanced depth of field by taking multiple images
at different focal points in a tissue slice, and combining
them into a single focused image (Media Cybernetics).
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Implantation of the injection cannulae into the PAG and
RVM was performed under halothane anesthesia. The
rats were placed in a stereotaxic apparatus (KOPF Model
900, David Kopf Instruments, CA) and stainless steel
26 G thin wall guide cannulae (C315G, PlasticsOne,
One, Roanoke, VA) were stereotaxically placed at either
PAG through a burr hole (AP: -7.6 mm, L: 0.7 mm,
H: 6.0 mm from Bregma) or RVM through a burr hole
(AP: 11.0 mm, L: 0.0 mm, H: 11.0 mm from Bregma).
Guide cannulae were affixed to the skull with stainless
steel screws and cranioplastic cement. 32.5 mg mefe-
namic acid (Daiichi-Sankyo, Tokyo, Japan) was orally
administered 2 times/day at 0 – 2 days after surgery for
postoperative pain control. The formalin inflammation
tests were performed 7 days after cannulae implantation.
All animals displayed normal feeding and drinking beha-
viors post-operatively. Rats showing neurological deficits
after cannulae implantation were not studied.
Drugs and microinjection
The NAAG peptidase inhibitor ZJ43 (IC50 = 2.4 nM, Ki =
0.79 nM for human glutamate carboxypeptidase II [28])
was synthesized following methods previously described
[28] and provided by Alan Kozikowski. LY341495, a highly
selective group II metabotropic glutamate receptor antag-
onist [50], was purchased from Tocris and injected i.p.
(1 mg/kg) in a total volume of 1 ml. ZJ43 and LY341495
were dissolved in saline. For the PAG and RVM microin-
jections, ZJ43 or saline was delivered in a total volume of
0.5 μl over a period of 60 seconds using a microsyringe
pump (EP-60, Eicom) and a 30 G stainless steel internal
cannula (C315G, Plastics One) connected via a polyethyl-
ene tube to a 10 μl Hamilton syringe.
At the completion of the experiment, 0.5 μl of India ink
was injected into the PAG or RVM 10 min before rats were
euthanized. The brains were fixed with formalin, and cor-
onal tissue sections were Nissl stained to confirm the
proper injection site. Only the rats whose microinjection
site was located within PAG or RVM were included in the
results.
Footpad inflammation test
In the formalin test, 50 μl of 5% formalin was injected
subcutaneously (SC) into the dorsal surface of the right
hind paw with a 25-gauge needle under brief halothane
anesthesia. Within 1 min after the formalin injection,
spontaneous flinching of the injected paw could be
observed. Flinching is readily discriminated and is char-
acterized as a rapid and brief withdrawal or flexion of
the injected paw. This pain-related behavior was quanti-
fied by counting the number of flinches for 1 min peri-
ods at 1–2 and at 5–6 min, and then for 1 min periods
at 5 min intervals from 10 to 60 min after the injection.Two phases of spontaneous flinching behavior were
observed: an initial acute phase (phase 1: during the first
6 min after the formalin injection) and a prolonged tonic
phase (phase 2: beginning about 10 min after the forma-
lin injection).
For the dose–response studies, ZJ43 was microinjected
into the PAG or RVM 10 min before the formalin injection
into the footpad. In the PAG studies, the peptidase inhibi-
tor was tested separately contralateral and ipsilateral to the
injected footpad. For the PAG, 150 μg treated group: n=7;
37.5 μg treated group: n=5; 3.75 μg treated group: n=6;
saline: n =6. To verify whether the effect of ZJ43 injected
to PAG contralateral to the formalin injection on the for-
malin test was mediated by the action of ZJ43 on the site
of injection, 150 μg (n=6) of ZJ43 was administered to the
PAG ipsilateral to the formalin injection 10 min before the
formalin injection. For the RVM, 150 μg treated group:
n=7; 15 μg treated group: n= 5; 1.5 μg treated group:
n=5; 0.15 μg treated group: n=5; saline: n = 7. To verify
that the analgesic effect of ZJ43 in the PAG and RVM was
mediated by the activation mGluR3, 1 mg/kg of LY341495
was administered (i.p.) 10 min before the microinjection of
ZJ43 (150 μg) into the PAG (n=7) or RVM (n=10).
Hot plate test
Rats were placed on a 52.5°C surface. The response la-
tency to either a hind-paw lick or a jump was recorded.
In the absence of a response, animals were removed
from the 52.5°C hot plate at 60 sec (cut-off time) and a
60 sec latency was assigned as the response.
Three baseline measurements were made before the
drug injection. ZJ43 (150 μg) was administered into
PAG (n = 4) or RVM (n = 4) and the hot-plate latency
was measured at 5, 15, 30, 45 and 60 min after the drug
injection. To obtain control data, the vehicle was
injected into PAG (n = 6) or RVM (n = 4).
Microdialysis and assay of glutamate and NAAG levels
Rats were anesthetized with Ketamine (80 mg/kg)/Xylazine
(5 mg/kg) (i.p.) and placed in a stereotaxic apparatus
(KOPF Inc., Tujunga, CA, USA) for surgical implantation
of a guide cannula. The guide cannula (SciPro Inc.,
Sanborn, NY, USA) was positioned to the (contralateral)
PAG according to the coordinates (AP, - 7.8; ML, -0.7; DV,
-4.4) or RVM according to the coordinates (AP, - 11.0; ML,
-0.7; DV, -9.0). The guide cannula was secured to the skull
with dental cement anchored by two stainless steel screws.
After surgery, each rat was individually housed and allowed
to recover for 24 hours before microdialysis and footpad
injection.
Microdialysis was carried out on conscious, freely
moving rats. Rats were lightly anesthetized with isofluor-
ane to facilitate manual insertion of the microdialysis
probe into the guide cannula. The stylet in the guide
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diameter, 0.6 mm; exposed tip, 2.0 mm; cut-off of 6 kDa;
SciPro Inc., Sanborn, NY, USA). The rats were tethered
to the awake animal system by means of a plastic collar
(CMA Microdialysis AB, Sweden). The probe was per-
fused at 2 μl/min with artificial cerebrospinal fluid
(CMA Microdialysis AB, Sweden). After at least 2 h to
reach equilibration, dialysate samples were collected
every 20 min. Three baseline fractions were collected be-
fore ZJ43 or saline injection. Pretreatment of ZJ43
(150 mg/kg i.p.) or saline occurred 15 min before inject-
ing formalin (5%, 50 μl) into the dorsal side of the left
hind-paw during microdialysis. Samples were subse-
quently analyzed for NAAG and glutamate. At the com-
pletion of each experiment, rats were euthanized and
brains were removed, fixed in 10% formalin and 30 μm
coronal sections prepared to confirm probe placement.
NAAG and glutamate analysis
Glutamate in the microdialysate samples was derivatized
with o-phthalaldehyde (OPA, Sigma, USA) and resolved by
reverse phase HPLC (Atlantis T3, ODS, 4.6× 150 mm,
3 μm) and electrochemical detection (Waters). Quantifica-
tion was obtained from standard curves prepared over a
glutamate range of 0.1–100 μM. Dialysate samples were
analyzed for NAAG content using radioimmunoassay as
previously described [48] with minor modifications. Briefly,
20 μl samples diluted to 50 μl with PBS were incubated
overnight at 4°C with 25 μl of NAAG antisera (1:25) and
25 μl of [3H]-NAAG (50,000 cpm, approximately 5 pmol).
After incubation, 900 μl of −20°C methanol was added,
precipitated proteins were separated by sedimentation at
15,000 x g for 15 min and tritium in the pellet and super-
natant was quantified. [3H]-NAAG bound to antibody in
unknown samples was compared to that of a standard
curve (0.033–3.3 μM NAAG) that was repeated with each
assay.
Statistical analysis
The time-response data are presented as the mean flinches
(± SEM) per minute for the periods of 1–2 min and 5–
6 min and then for 1 min periods at 5 min intervals up to
60 min. For the dose–response analysis, data from phase 1
(0–2 min) and phase 2 (10–60 min) observations were
considered separately. In each case, the cumulative in-
stances of formalin-evoked flinches during the phase 1 and
phase 2 were calculated for each rat. These individual rat
data were then used to construct phase 1 and phase 2
dose–response curves. For dose–response data and tests of
the efficacy of LY341495, one-way ANOVA was used with
Tukey post-hoc test.
For the analysis of drug effect, the % maximum possible
effect was calculated, where % maximum possible effect =
([post-drug maximum latency – pre-drug latency]/[cut-off time (60 sec) – pre-drug latency]) x 100. The post drug
maximum latency was defined as the single longest la-
tency during the entire time course of the hot plate test.
To analyze the effect of ZJ43 on % maximum possible ef-
fect, an unpaired t-test was used.
Microdialysis data are expressed as percentage of basal
values (calculated as means of the three samples before
injections). Data on the responses following ZJ43 injection
in the ipsilateral versus contralateral PAG were compared
using Students t-test. The basal concentrations of NAAG
and glutamate in the dialysates, uncorrected for recovery,
were 0.053± 0.006 μM and 1.25± 0.13 μM in PAG,
0.074± 0.005 μM and 0.82± 0.07 μM in RVM respectively.
The values were expressed as a % of baseline level for each
rat and the mean and standard error were determined for
each treatment group. Two-factor ANOVA for repeated
measurements was used to examine the possibility of sig-
nificant differences (p <0.05) between groups followed by
Tukey post hoc test.
Microdialysis data are expressed as percentage of basal
values calculated independently for each animal as mean of
the three samples taken before injections. All data were
given as mean± standard error of the mean (S.E.M.) and
not corrected for ‘recovery’ of the dialysis procedure. Gen-
eral Linear Model with repeated measurements (SPSS19
for Windows) was used to examine the possibility of sig-
nificant differences (p< 0.05) between groups followed by
a Student’s t-test for every time-point.
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